No Data
No Data
No Data
No Data
No Data
Assessing BioNTech: Insights From 11 Financial Analysts
Ratings for BioNTech (NASDAQ:BNTX) were provided by 11 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.Summarizing their recent assessments, the table below ill
BenzingaApr 17 10:00 ET
Express News | HC Wainwright & Co. Reiterates Buy on BioNTech, Maintains $107 Price Target
Moomoo 24/7Apr 17 06:24 ET
Analysts Are Bullish on These Healthcare Stocks: BioNTech SE (BNTX), Connect Biopharma Holdings (CNTB)
TipRanksApr 17 06:20 ET
TROP-2 Inhibitors Market to Boost by 2034, Predicts DelveInsight | Key Companies to Look Out - Daiichi Sankyo, AstraZeneca, Kelun Biotech, Merck, DualityBio, BioNTech, BiOneCure Therapeutics
New York, USA, April 09, 2024 (GLOBE NEWSWIRE) -- TROP-2 Inhibitors Market to Boost by 2034, Predicts DelveInsight | Key Companies to Look Out - Daiichi Sankyo, AstraZeneca, Kelun Biotech, Merck, DualityBio,
GlobeNewswireApr 9 13:00 ET
BioNTech SE Virtual AGM Scheduled for May 2024
TipRanksApr 8 17:27 ET
BioNTech Reports Positive 3-Year Data From Phase 1 Trial of Cevumeran in Pancreatic Cancer
BioNTech (BNTX) said Sunday that three-year follow-up data from a phase 1 trial on its immunotherapy candidate cevumeran in patients with resected pancreatic ductal adenocarcinoma, or PDAC, showed tha
MT NewswiresApr 8 06:18 ET
No Data
No Data
101878107 : really?